AR067010A1 - FORMULATIONS OF LIOFILIZED IMMUNOGLOBULIN AND METHODS FOR PREPARATION - Google Patents
FORMULATIONS OF LIOFILIZED IMMUNOGLOBULIN AND METHODS FOR PREPARATIONInfo
- Publication number
- AR067010A1 AR067010A1 ARP080102544A AR067010A1 AR 067010 A1 AR067010 A1 AR 067010A1 AR P080102544 A ARP080102544 A AR P080102544A AR 067010 A1 AR067010 A1 AR 067010A1
- Authority
- AR
- Argentina
- Prior art keywords
- liofilized
- immunoglobulin
- formulations
- preparation
- methods
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000013011 aqueous formulation Substances 0.000 abstract 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000012931 lyophilized formulation Substances 0.000 abstract 1
- 229960005027 natalizumab Drugs 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicacion 1: Una formulacion liofilizada estable elaborada liofilizando una formulacion acuosa, donde la formulacion acuosa comprende: (a) entre aproximadamente 20 mg/ml y aproximadamente 80 mg/ml de natalizumab; (b) un bufer con un pH de aproximadamente 5,5 a aproximadamente 6,5; (c) entre aproximadamente 20 mg/ml y aproximadamente 80 mg/ml de sacarosa; y (d) entre aproximadamente 0,02 y aproximadamente 0,08% de polisorbato.Claim 1: A stable lyophilized formulation made by lyophilizing an aqueous formulation, wherein the aqueous formulation comprises: (a) between about 20 mg / ml and about 80 mg / ml of natalizumab; (b) a buffer with a pH of about 5.5 to about 6.5; (c) between about 20 mg / ml and about 80 mg / ml of sucrose; and (d) between about 0.02 and about 0.08% polysorbate.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92913307P | 2007-06-14 | 2007-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067010A1 true AR067010A1 (en) | 2009-09-30 |
Family
ID=40897430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102544 AR067010A1 (en) | 2007-06-14 | 2008-06-13 | FORMULATIONS OF LIOFILIZED IMMUNOGLOBULIN AND METHODS FOR PREPARATION |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR067010A1 (en) |
| CL (1) | CL2008001778A1 (en) |
| PE (1) | PE20090767A1 (en) |
| TW (1) | TW200909005A (en) |
| ZA (1) | ZA200909090B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102735988B1 (en) * | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | therapeutic antibody preparations |
-
2008
- 2008-06-13 TW TW97122278A patent/TW200909005A/en unknown
- 2008-06-13 AR ARP080102544 patent/AR067010A1/en unknown
- 2008-06-16 CL CL2008001778A patent/CL2008001778A1/en unknown
- 2008-06-16 PE PE2008001028A patent/PE20090767A1/en not_active Application Discontinuation
-
2009
- 2009-01-01 ZA ZA200909090A patent/ZA200909090B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200909005A (en) | 2009-03-01 |
| PE20090767A1 (en) | 2009-06-24 |
| ZA200909090B (en) | 2010-08-25 |
| CL2008001778A1 (en) | 2008-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6251275A2 (en) | FORMULATIONS OF LIOFILIZED IMMUNOGLOBULIN AND METHODS FOR PREPARATION | |
| AR130402A2 (en) | ANTI-PDL1 ANTIBODIES FORMULATIONS | |
| ES2676205T3 (en) | Stable antibody formulations for the human PD-1 receptor of programmed death and related treatments | |
| AR117403A2 (en) | ANTIBODY FORMULATIONS | |
| AR090272A1 (en) | FORMULATION OF ANTIBODIES Ab | |
| AR079556A1 (en) | FORMATION OF ANTIBODIES | |
| CL2011001406A1 (en) | "Stable liquid pharmaceutical formulation comprising an antibody to il-1beta (acz885), mannitol, histidine buffer and polysorbate 80, with a pH between 5.5-7.0". | |
| PE20071111A1 (en) | METHODS TO MODULATE THE MANNOSE CONTENT OF RECOMBINANT PROTEINS | |
| WO2007147001A3 (en) | Lyophilized formulations of anti-egfr antibodies | |
| AR082630A1 (en) | ANTI-TENASCINE-C A2 ANTIBODIES AND METHODS OF USE | |
| AR117913A2 (en) | DRUG-ANTIBODY CONJUGATE, PHARMACEUTICAL COMPOSITION AND ITS USES | |
| NZ705178A (en) | Anti-prolactin receptor antibody formulations | |
| PE20141151A1 (en) | CD27L ANTIGEN BINDING PROTEINS | |
| CR20190400A (en) | MONOCLONAL ANTI-VRS ANTIBODY FORMULATIONS | |
| CY1119342T1 (en) | THREE-PART OX40-ANOSOPHEIN FUEL PROTEIN AND METHODS OF USE | |
| CU24058B1 (en) | PCSK9 ANTAGONISTS | |
| CY1115413T1 (en) | FSH RECOVERED THAT INCLUDES ALPHA 2,3- AND ALPHA 2 ', 6-SIALYLATION | |
| PE20151524A1 (en) | GENETICALLY MANIPULATED ANTI-IL-23p19 ANTI-IL-23p19 ANTIBODIES SOLUTION FORMULATIONS | |
| EP2582719A4 (en) | INSULIN AGONISTS WITH ONE SINGLE CHAIN VERY ACTIVE AT THE INSULIN RECEPTOR | |
| MX348152B (en) | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof. | |
| PE20130643A1 (en) | CONJUGATES OF MULTIFUNCTIONAL ANTIBODIES | |
| PE20120532A1 (en) | ANTI-ActRIIB ANTIBODIES | |
| AR060667A1 (en) | INCREASE TITLE FOR VACCINATION IN ANIMALS | |
| AR095496A1 (en) | FORMULATIONS OF ANTIBODIES ANTI-RECEIVER OF PROLACTIN | |
| PE20081687A1 (en) | FUSION PROTEIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |